Status:
COMPLETED
Ocular Surface Syndrome Post-lasik, Outcomes of Treatment With Platelet Rich Plasma
Lead Sponsor:
Vissum, Instituto Oftalmológico de Alicante
Conditions:
Dry Eye After LASIK-Laser in Situ Keratomileusis
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
To evaluate the efficacy of autologous platelet-rich plasma eye drops (E-PRP) for the treatment of chronic ocular surface syndrome (OSS) following laser in situ keratomileusis (LASIK).
Detailed Description
Prospective interventional consecutive case series including 156 eyes of 80 patients affected by chronic post-LASIK OSS who were treated with autologous E-PRP 6 times a day as monotherapy for 6 weeks....
Eligibility Criteria
Inclusion
- Adult patients suffering from moderate to severe dry eye syndrome for 6 months or more after conventional treatments with artificial tears following LASIK.
- Tear break-up time (TBUT) between 4 and 9 seconds.
Exclusion
- Ocular pathology needing topical treatments different than dry eye syndrome
- Trombocitopeny, associated pathologies to coagulation factors or any state of plaquets antiagregation (AAS and other AINES).
- Ocular tumours, corneal distrophies, history of ocular herpes.
- Pregnant or nursering women.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 17 2013
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03322917
Start Date
July 1 2008
End Date
January 17 2013
Last Update
December 4 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.